Get 20% off this month when you try our services!
Our startup (AIONCDYN)
Founder’s Statement
At AIONCDYN, our mission is to pioneer the forefront of oncological research through the integration of artificial intelligence and computational structural modeling. We are dedicated to advancing the field of anticancer therapies by leveraging cutting-edge technologies and innovative methodologies.
Our goal is to contribute significantly to the development of novel therapeutic strategies that target cancer with unprecedented precision and efficacy. By harnessing the power of AI, we aim to elucidate complex biological pathways, predict drug interactions, and design optimized therapeutic agents that can revolutionize cancer treatment.
AIONCDYN is committed to pushing the boundaries of what is possible in computational biology. We strive to create a paradigm shift in cancer therapy development by utilizing high-throughput data analysis, machine learning algorithms, and advanced structural modeling techniques. Our research endeavors are focused on accelerating the discovery of potent anticancer compounds and enhancing the therapeutic index of existing treatments.
Through our innovative approaches, AIONCDYN aspires to make a profound impact on the lives of cancer patients worldwide. We believe that our interdisciplinary efforts will lead to breakthroughs that redefine the landscape of cancer therapeutics and offer new hope to those affected by this devastating disease.
Together, we can transform the future of cancer treatment and bring about a new era of precision medicine.
Founder & CEO
Aamir Mehmood, Ph.D.
A glimpse of our contribution towards cancer research!!!
Bringing Structural Implications and Deep Learning-Based Drug Identification for KRAS Mutants
Ranking breast cancer drugs and biomarkers identification using machine learning and pharmacogenomics.
DDSBC: A stacking ensemble learning model for drug-pair cell synergy classification for breast cancer
Unveiling the Therapeutic Potential of Paclitaxel Combinations Against Breast Carcinoma and Identification of In Vivo Biomarkers
Mutational impacts on the N and C terminal domains of the MUC5B protein: a transcriptomics and structural biology study
Read our book
Bridging Chemistry & Medicine...
Drug development costs are rising, and investment returns are falling, with FDA-approved new molecular entities (NMEs) in decline. This is partly due to adverse side effects and reduced efficiency of many compounds, impacting both the pharmaceutical industry and patients with limited treatment options.
Advances in computational chemistry, computer science, structural biology, and molecular biology have enhanced drug design and shortened discovery times. By integrating cheminformatics, bioinformatics, and systems biology, we can better understand disease mechanisms and identify lead molecules, improving drug safety, efficacy, and approval rates.
This book addresses the lack of fundamental knowledge about computational tools in drug discovery, offering recent bioinformatics and cheminformatics approaches and their integration with systems biology. It is aimed at researchers, academics, and advanced students in these fields.
